Results of return-to-play screening in junior competitive athletes after SARS-CoV-2 infection: data are presented according to different age groups
| Variables | <14 years (n=290) | ≥14 years (n=281) | Overall P value |
| Asymptomatic during COVID-19, n (%) | 162 (55.8) | 188 (66.9) | 0.002 |
| Symptom duration (days) | 4.1±8.4 | 3.2±8.0 | 0.56 |
| Resting HR (bpm) | 81±15 | 75±14 | <0.0001 |
| Echocardiography | |||
| LV EDD (mm) | 43.9±4.5 | 48.0±4.5 | <0.0001 |
| LV ESD (mm) | 25.9±4.2 | 29.5±4.1 | <0.0001 |
| LV EF (%) | 63.8±4.9 | 63.2±4.5 | 0.14 |
| Mid-cavity RV diameter (mm) | 27.2±6.6 | 29.3±7.7 | 0.01 |
| s’ velocity (m/s) | 0.14±0.02 | 0.14±0.02 | 0.71 |
| Aortic root (mm) | 25.6±3.3 | 28.6±3.6 | <0.0001 |
| Ascending aorta (mm) | 23.6±3.1 | 26.5±3.4 | <0.0001 |
| Aortic arch (mm) | 19.9±2.9 | 22.6±2.2 | <0.0001 |
| Pericardial involvement, n (%) | 7 (2.4) | 11 (3.9) | 0.31 |
| Pericarditis, n (%) | 0 (0) | 2 (0.7) | 0.98 |
HR, heart rate; LV, left ventricular; EDD, end-diastolic diameter; ESD, end-systolic diameter; EF, ejection fraction; RV, right ventricular.